Informed Managed Care Decision-Making in the Treatment and Management of Ovarian Cancer: Optimizing the Impact of PARP Inhibitors for Improved Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2023 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2023 to August 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme LLC

There were an estimated 19,880 new cases of ovarian cancer last year in the United States, and an estimated 12,8110 deaths due to ovarian cancer in the US, according to the American Cancer Society. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. This is due in large part to a lack of symptoms during the earlier stages. The five year survival rate is only 45%. Fortunately for patients with ovarian cancer, the treatment paradigm has exploded in the past three years, giving medical directors and clinicians more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are poly (ADP-ribose) polymerase (PARP) inhibitors, which have shown improved efficacy for patients with ovarian cancer. Additionally, new indications for these targeted agents offer expanded options in the maintenance setting in the first-line setting. It is important for medical directors, oncologists, and nurses who manage ovarian cancer patient populations to have a solid understanding of the mechanistic rationale for the use of these medications in order to optimize their therapeutic application.

Upon completion of this activity, participants will be able to:

  • Assess the clinical and economic burden of ovarian cancer, including factors that contribute to poor prognosis and increased costs

  • Explore the nuances that differentiate the available PARP inhibitors that aid in guiding treatment selection

  • Examine guideline recommendations and recent clinical data on the use PARP inhibitors in various stages of treatment in ovarian cancer

  • Identify patients with advanced ovarian cancer for whom a PARP inhibitor is an appropriate choice for the next step in the management of their cancer

  • Evaluate practical strategies to recognize and manage adverse events related to PARP inhibitor use ovarian cancer, particularly in the long-term maintenance setting

  • Determine the cost of care and utilization management strategies to optimize the use of PARP inhibitors in the treatment of ovarian cancer


Faculty: Kathleen N. Moore, MD, MS
Associate Director, Clinical Research
Virginia Kerley Cade Chair in Developmental Therapeutics
Director, TSET Phase I Drug Unit
Co-Director, Cancer Therapeutics Program
Stephenson Cancer Center at the University of Oklahoma HSC


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Moore has served as a consultant for Aadi, AstraZeneca, Alkemeres, Aravive, Blueprint, Clovis, Caris, Eisai, GSK/Tesaro, Genentech/Roche, Immunogen, Lilly, Mereo, Mersana, Myriad, Merck, Novartis, OncXerna, OncoNova, VBL Therapeutics, and Pannavance. Her presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue